Gland Pharma (NSE:GLAND) Inventories, Finished Goods: ₹0 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
84 GF Score
Price ₹2,495.80
GF Value ₹2,135.67
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Inventories, Finished Goods?

Gland Pharma NSE:GLAND -2.13% 84 Inventories, Finished Goods is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,135.67 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Gland Pharma's annual finished goods increased from Mar. 2024 (₹866 Mil) to Mar. 2025 (₹943 Mil) but then declined from Mar. 2025 (₹943 Mil) to Mar. 2026 (₹0 Mil).

Gland Pharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Inventories, Finished Goods Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only 591.47 886.68 866.21 943.31 0.00

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 943.31 0.00 0.00 0.00 0.00
NSE:GLAND
84GF Score
Gland Pharma Ltd NSE:GLAND
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ₹0 Mil mean?
Gland Pharma (NSE:GLAND) has a Inventories, Finished Goods of ₹0 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Inventories, Finished Goods too high?
Gland Pharma's current Inventories, Finished Goods is ₹0 Mil. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Inventories, Finished Goods compare to ZTS and UTHR?
Gland Pharma's Inventories, Finished Goods of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Gland Pharma and its competitors. Gland Pharma's current Inventories, Finished Goods is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,135.67, compared to a current price of ₹2,495.80 — trading 16.9% above its estimated fair value. The current Inventories, Finished Goods is ₹0 Mil. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Inventories, Finished Goods is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,495.80 is trading 16.9% above its estimated GF Value™ of ₹2,135.67. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Inventories, Finished Goods: ₹0 Mil
  • GF Value™: ₹2,135.67 vs. price of ₹2,495.80 (16.9% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score

Get the complete analysis for NSE:GLAND

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,495.80
Price
₹2,135.67
GF Value